About

I'm a product and research leader working at the intersection of artificial intelligence, human-computer interaction, and psychiatry. I'm interested in how AI can transform how we understand, prevent, and treat mental illness.

I'm a part-time PhD candidate in Psychiatry at the University of Cambridge, focused on applied AI and computational psychiatry.

At the same time, I'm also a Group Product Manager at Tempus AI, where I lead the AI Biomarker Platform and the Neurology & Psychiatry product portfolio. I also serve on the US Gov. Foundation for the NIH's steering committee for MAP-D, a public-private partnership developing biomarkers for depressive disorders.

Previously, I was Product Lead for Psychiatry AI/ML at Verily (Google Life Sciences), where I led the psychiatry and behavioral health portfolio, including AI/ML digital biomarkers across linguistics, paralinguistics, and mobile sensors; real-world evidence registries in depression; and EHR-based LLMs for suicide/NSSI risk factor detection. Before Verily, I was an AI research scientist at Stanford Medicine Department of Psychiatry working on FAccT deep learning applications in psychiatry.

I hold an M.S. in Computer Science (Biocomputation) and a B.S. in Symbolic Systems (AI) from Stanford University.

Selected Publications

Increasing psychopharmacology clinical trial success rates with digital measures and biomarkers.
Reiter JE, Nickels S, Nelson B, Rainaldi E, Peng L, Kapur R, Abernethy A, Trister A.
Nature Neuropsychopharmacology: Digital Psychiatry and Neuroscience, 2(7). 2024.
Associations between testosterone and future PTSD symptoms among middle age and older UK residents.
Shen H, Stafford C, Meijsen J, Zhang L, Reiter JE, Lawn RB, Smith AK, Vemuri M, Duncan LE.
Nature Translational Psychiatry. 2024.
Identifying a stable and generalizable factor structure of major depressive disorder across three large longitudinal cohorts.
Tseng V, Tharp J, Reiter JE, Ferrer W, Hong DS, Doraiswamy PM, Nickels S, Project Baseline Health Study Research Group.
Psychiatry Research, 333. 2024.
Reducing health anxiety in patients with inflammatory bowel disease using video testimonials: pilot assessment of a video intervention.
Shor J, Miyatani Y, Arita E, Chen P, Ito Y, Kayama H, Reiter JE, Kobayashi K, Kobayashi T.
JMIR Formative Research, 7. 2023.
Developing an interpretable schizophrenia deep learning classifier on fMRI and sMRI using a patient-centered DeepSHAP.
Reiter JE.
32nd Conference on Neural Information Processing Systems (NeurIPS). 2020.

Experience

Tempus AI — Group Product Lead, AI Biomarker Platform & Neurology/Psychiatry
2025 – Present
University of Cambridge — PhD Candidate, Computational Psychiatry (Part-Time)
2024 – Present
US Gov. Foundation for the NIH — Steering Committee Member, MAP-D Depression Biomarker Public-Private Partnership
2024 – Present
Compass Pathways, Stealth Spin-Out — VP, Product & Translational Research
2024 – 2025
Verily (Google Life Sciences) — Product Lead, Psychiatry AI/ML
2021 – 2024
Previously Product Manager, Digital Biomarkers (2022 – 2023)
Previously Associate Product Manager (2021 – 2022)
Stanford Medicine, Dept. of Psychiatry — AI/ML Research Scientist
2020 – 2022

Education

University of Cambridge
Ph.D., Psychiatry (Applied AI, Computational Psychiatry) — Part-Time
Expected 2028
Stanford University
M.S., Computer Science (Biocomputation), 4.17
2021
Stanford University
B.S., Symbolic Systems (Artificial Intelligence), with Distinction, 4.02
Phi Beta Kappa
2020